◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › ANIX

Anixa Biosciences, Inc. (ANIX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-24

Anixa Biosciences, Inc. (ANIX) operates in the Biotechnology industry and is headquartered in San Jose, United States with about 4 employees. Its market capitalization is roughly $128 million. In the fiscal year ended 2025-10-31, ANIX reported $0M in revenue and ($11M) in net income.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.

Interactive charts & full statements →

ANIX Revenue & Earnings History — Annual Income Statement

Income statement2025-10-312024-10-312023-10-312022-10-312021-10-31
Total Revenue$0M$0M$0M$0M
Gross Profit$0M$0M$0M$0M
Operating Income (EBIT)($12M)($14M)($11M)($14M)
Net Income($11M)($13M)($10M)($14M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANIX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-31
Total Revenue$0M$0M$0M$0M$0M
Gross Profit$0M
Operating Income (EBIT)($3M)($3M)($3M)($2M)($3M)
Net Income($2M)($3M)($3M)($2M)($3M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ANIX Free Cash Flow History

ANIX Balance Sheet History

Balance sheet2025-10-312024-10-312023-10-312022-10-312021-10-31
Total Assets$16M$22M$26M$30M
Total Liabilities$2M$3M$2M$2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANIX viewer.

Other Companies in Biotechnology

← ANIPAll stocksANNA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.